Clinical trials: DAPT(Dual Antiplatelet Therapy)
Optical Coherence Tomography, Dual Antiplatelet Therapy
OCT or Angiography Guided De-escalation of DAPT
Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus.
- Conditions
- Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage
- Trial name
- NCT06339021
- Testing
- OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shenyang Northern Hospital
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Percutaneous Transluminal Coronary Angioplasty, Coronary Disease
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.
- Trial name
- BVS LATE (NCT02939872)
- Testing
- aspirin and clopidogrel, Clopidogrel only
- Where
- 2 sites in South Korea
- Volunteers
- 238 people
- Sponsor
- Seung-Jung Park
Aneurysm Cerebral (Unruptured)
Dual Antiplatelet Therapy Adherence With Reminder App Usage
The purpose of this study is to evaluate Dual Antiplatelet Therapy adherence in patients undergoing stent-based endovascular treatment for unruptured cervical and intradural, intracranial aneurysms.
- Trial name
- NCT05071027
- Testing
- Endovascular Neurosurgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Montefiore Medical Center
Myocardial Infarction, Cardiovascular Disease
Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
OBJECTIVE OF THE STUDY: To test the hypothesis that 6 months DAPT (Dual anti-platelet therapy) after second generation DES (Drug Eluting Stent) implantation in STEMI (ST elevation Myocardial Infarction) is not inferior to 12…
- Trial name
- DAPT-STEMI (NCT01459627)
- Testing
- 6 months DAPT, 12 months DAPT
- Where
- 16 sites in Netherlands, Norway and 2 more
- Volunteers
- 1,100 people
- Sponsor
- Maasstad Hospital
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute
Coronary Artery Disease (CAD)
1-Month Versus 6-Month Dual Antiplatelet Therapy After Successful Drug-Coated Balloon-Only Percutaneous Coronary Intervention
This study will compare the clinical outcomes of a 1-month dual antiplatelet therapy (DAPT) strategy with a standard 6-month DAPT strategy in patients undergoing successful drug-coated balloon-only percutaneous coronary…
- Trial name
- ADAPT-DCB (NCT07879430)
- Testing
- 1-Month DAPT, 6-Month DAPT
- Volunteers
- 1,258 people
- Sponsor
- Ulsan University Hospital
Coronary Artery Disease
Bioflow-DAPT Study
BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study. A total of 1'948 subjects will be randomized 1:1 to receive either Orsiro Mission or Resolute Onyx.
- Trial name
- NCT04137510
- Testing
- Percutaneous coronary intervention
- Where
- 53 sites in Australia, Austria and 16 more
- Volunteers
- 1,948 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
EVOLVE Short DAPT Study
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
- Trial name
- NCT02605447
- Testing
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Where
- 110 sites in United States, Brazil and 5 more
- Volunteers
- 2,009 people
- Sponsor
- Boston Scientific Corporation
Acute Coronary Syndrome (ACS)
OPTImal Management of Antithrombotic Agents: OPTIMA-5
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI) in China.
- Trial name
- NCT04116931
- Testing
- Switch ticagrelor to clopidogrel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Dual Antiplatelet Therapy, Acute Coronary Syndrome
De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
High bleeding risk (HBR) patients, comprising up to 50% of those presenting with acute coronary syndrome (ACS), are a high-risk group that is increasing in size due to an aging population.
- Conditions
- Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- DESC-HBR (NCT05903976)
- Testing
- P2Y12 inhibitor de-escalation
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Coronary Artery Disease, Acute Coronary Syndromes
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndromes, Chronic Coronary Syndrome, Percutaneous Coronary Intervention
- Trial name
- ASPIRE-LD (NCT07846462)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- China
- Volunteers
- 2,640 people
- Sponsor
- Jilin University
Coronary Artery Disease, Myocardial Ischemia
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases
- Trial name
- NCT04624854
- Testing
- Clopidogrel and aspirin dual-antiplatelet therapy, Aspirin monotherapy
- Where
- 97 sites in China
- Volunteers
- 8,250 people
- Sponsor
- Harbin Medical University
Coronary Artery Disease, Acute Myocardial Infarction
HOST - DAPT Duration According the Bleeding Risk
Dual antiplatelet agent therapy (DAPT) is essential in treating PCI patients. DAPT can minimize thrombotic adverse events that occur not only at the stented lesion, but along the whole coronary tree.
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction, Stable Angina
- Trial name
- HOST-BR (NCT05631769)
- Testing
- Dual antiplatelet agent duration
- Where
- South Korea
- Volunteers
- 4,900 people
- Sponsor
- Seoul National University Hospital
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
PCI Patients, DAPT(Dual Antiplatelet Therapy)
Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study
Percutaneous coronary intervention (PCI) is commonly used to treat stable ischemic heart disease. Among patients, 7.5% require surgical treatment, and up to 20% may need noncardiac surgery (NCS) within two years.
- Conditions
- PCI Patients, DAPT(Dual Antiplatelet Therapy), Hip Fracture Surgeries
- Trial name
- NCT07024446
- Testing
- The time interval between PCI and NCS
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University Union Hospital
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Aortic Valve Stenosis
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs. dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac CT imaging) and cerebral embolization…
- Trial name
- ADAPT-TAVR (NCT03284827)
- Testing
- NOAC, DAPT
- Where
- 5 sites in Hong Kong, South Korea and 1 more
- Volunteers
- 235 people
- Sponsor
- Duk-Woo Park, MD
Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary.
- Trial name
- OPT-BIRISK (NCT03431142)
- Testing
- Clopidogrel, Clopidogrel+aspirin
- Where
- 103 sites in China
- Volunteers
- 7,758 people
- Sponsor
- Shenyang Northern Hospital